<p>The number of persons with non-B virus receiving the NRTI tenofovir (ten), the NNRTI delavirdine (three), and the PIs amprenavir (13) and lopinavir (28) are not shown. 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; DDC, zalcitabine; DDI, didanosine; EFV, efavirenz; IDV, indinavir; NFV, nelfinavir; NVP, nevirapine; RTV, ritonavir; SQV, saquinavir.</p
<p><b>Copyright information:</b></p><p>Taken from "Injection drug use and patterns of highly active ...
<p>Prevalence of susceptible (S, solid bars), intermediate (I, striped bars) or high-level resistanc...
<p>Prevalence of susceptible (S, white), intermediate (I, grey) or high-level resistance (R, black) ...
<p>Prevalence of susceptible (S, dotted bars), intermediate (I, striped bars) or high-level resistan...
<p>Nucleotide/side reverse transcriptase inhibitors (N(t)RTIs): lamivudine (3TC), tenofovir (TDF), z...
<p>a) Drug classes. NRTIs not represented as there was a single patient that initiated a regimen wit...
<p>The mutations that were not detected in either treatment groups are not included. The numbers rep...
a<p>All except 5 received NRTIs as part of the first regimen. A few received mono- or duo-therapy or...
<p>AZT: zidovudine; 3TC: lamivudine; EFV: efavirenz;</p><p>NEV: nevirapine; FTC: emtricitabine;</p><...
<p>ABC, abacavir; AZT, zidovudine; APV, amprenavir; AZV, atazanavir; d4T, stavudine; ddI, didanosine...
<p>A Lamivudine, Zidovudine/Stavudine with Nevirapine or Efavirenz</p><p>B Lamivudine, Tenofovir wit...
<p>LPVr-NVP, ritonavir boosted lopinavir-based regimen followed by switch to nevirapine-based regime...
<p>PIs: protease inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; NNRTIs: non-nucleos...
<p>The frequencies of the 20 most-frequent drug combinations in EuResistTCE (a) and HIVdbTCE (b) dat...
We compared use of a 3-class regimen (nevirapine [Nvp], stavudine [d4T], and indinavir [Idv; 1000 mg...
<p><b>Copyright information:</b></p><p>Taken from "Injection drug use and patterns of highly active ...
<p>Prevalence of susceptible (S, solid bars), intermediate (I, striped bars) or high-level resistanc...
<p>Prevalence of susceptible (S, white), intermediate (I, grey) or high-level resistance (R, black) ...
<p>Prevalence of susceptible (S, dotted bars), intermediate (I, striped bars) or high-level resistan...
<p>Nucleotide/side reverse transcriptase inhibitors (N(t)RTIs): lamivudine (3TC), tenofovir (TDF), z...
<p>a) Drug classes. NRTIs not represented as there was a single patient that initiated a regimen wit...
<p>The mutations that were not detected in either treatment groups are not included. The numbers rep...
a<p>All except 5 received NRTIs as part of the first regimen. A few received mono- or duo-therapy or...
<p>AZT: zidovudine; 3TC: lamivudine; EFV: efavirenz;</p><p>NEV: nevirapine; FTC: emtricitabine;</p><...
<p>ABC, abacavir; AZT, zidovudine; APV, amprenavir; AZV, atazanavir; d4T, stavudine; ddI, didanosine...
<p>A Lamivudine, Zidovudine/Stavudine with Nevirapine or Efavirenz</p><p>B Lamivudine, Tenofovir wit...
<p>LPVr-NVP, ritonavir boosted lopinavir-based regimen followed by switch to nevirapine-based regime...
<p>PIs: protease inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; NNRTIs: non-nucleos...
<p>The frequencies of the 20 most-frequent drug combinations in EuResistTCE (a) and HIVdbTCE (b) dat...
We compared use of a 3-class regimen (nevirapine [Nvp], stavudine [d4T], and indinavir [Idv; 1000 mg...
<p><b>Copyright information:</b></p><p>Taken from "Injection drug use and patterns of highly active ...
<p>Prevalence of susceptible (S, solid bars), intermediate (I, striped bars) or high-level resistanc...
<p>Prevalence of susceptible (S, white), intermediate (I, grey) or high-level resistance (R, black) ...